HealthcareServices

Cancer Profiling Market Future Outlook 2026: Key Drivers and Growth Potential

February 20, 2026February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the cancer profiling market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Cancer Profiling Market covering 2026–2035?

The cancer profiling market has experienced swift expansion in recent years. Its value is projected to rise from $15 billion in 2025 to $16.67 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.1%. This historical growth can be attributed to factors such as increasing cancer incidence rates, the expansion of molecular diagnostics laboratories, the early adoption of genomic testing in oncology, the growth in research-based cancer profiling, and the rising availability of diagnostic platforms.

The cancer profiling market is poised for significant expansion over the coming years. By 2030, this market is projected to reach $25.62 billion, exhibiting a compound annual growth rate (CAGR) of 11.3%. This anticipated growth is driven by several factors, including the escalating demand for precision medicine approaches, the broadening scope of companion diagnostics, the increasing adoption of liquid biopsy technologies, greater investments in oncology diagnostics, and the enhanced incorporation of profiling into standard clinical procedures. Key trends expected during this period involve the rising uptake of ngs-based cancer profiling, the expanding utilization of comprehensive genomic panels, the increasing incorporation of AI in data interpretation, the widening availability of personalized oncology diagnostics, and a heightened emphasis on early molecular detection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Cancer Profiling Market?

A rise in cancer cases is expected to propel the growth of the cancer profiling market in the coming years. Cancer incidence refers to the number of new cancer diagnoses observed in a specific population over a given timeframe. This elevated occurrence of cancer is caused by urbanization, an expanding aging population, evolving lifestyles, and environmental and genetic factors. Cancer profiling assists in pinpointing distinct molecular or genetic changes within a tumor, such as gene mutations or other alterations in tumor DNA, which proves beneficial in the cancer treatment cycle. For instance, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that in 2023, an estimated 165,000 Australians received a new cancer diagnosis, which equates to over 450 cases each day, and males accounted for about 55% of these diagnoses. Therefore, the increasing incidence of cancer is driving the growth of the cancer profiling market.

What Segments Are Identified Within The Structure Of The Cancer Profiling Market?

The cancer profiling market covered in this report is segmented –

1) By Technology: Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-Generation Sequencing), Microarrays, In-Situ Hybridization

2) By Biomarker Type: Genomic Biomarkers, Protein Biomarkers

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancers

4) By Application: Research Applications, Clinical Applications, Diagnostics, Prognostics, Other Applications

Subsegments:

1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Luminex xMAP Technology

2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR)

3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq)

4) By Microarrays: DNA Microarrays, RNA Microarrays, SNP Arrays

5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)

Which Market Trends Are Opening Growth Opportunities In The Cancer Profiling Market?

Leading companies in the cancer profiling market are concentrating on technological breakthroughs, such as concurrent whole-exome sequencing (WES) and whole-transcriptome sequencing (WTS) assays. These innovations aim to offer more exhaustive, tissue-saving, and clinically applicable molecular diagnostics crucial for precision oncology. These assays integrate DNA (exome) and RNA (transcriptome) analysis within a singular workflow, allowing for the detection of genomic variants (including SNVs, indels, and copy-number alterations) alongside gene expression or fusion events, a contrast to conventional NGS tests that demand separate assays or use restricted gene panels. For example, in November 2024, Caris Life Sciences, a US-based precision medicine firm, obtained FDA approval for MI Cancer Seek. This NGS in vitro diagnostic is designed to perform WES and WTS simultaneously. The assay employs total nucleic acid (TNA) from FFPE tumor tissue to identify single-nucleotide variants, insertions or deletions across 228 genes, microsatellite instability (MSI), tumor mutational burden (TMB), and copy-number amplifications, particularly in breast cancer. By consolidating DNA and RNA profiling into one test, it preserves tissue, yields clinically actionable companion diagnostic (CDx) indications for various tumor types, and expedites therapy selection by providing a unified genomic blueprint.

Which Major Industry Participants Are Leading The Cancer Profiling Market Growth?

Major companies operating in the cancer profiling market are Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Cancer Profiling Market?

North America was the largest region in the cancer profiling market in 2025. The regions covered in the cancer profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cancer Profiling Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9912&type=smp

Browse Through More Reports Similar to the Global Cancer Profiling Market 2026, By The Business Research Company

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Cancer Tumor Profiling Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

Cancer Biomarker Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795